Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vinflunine: a novel antitubulin agent in solid malignancies.

Jaafar Bennouna1, Mario Campone, Jean Pierre Delord

  • 1Centre René Gauducheau, Saint-Herblain, France. j-bennouna@nantes.fnclcc.fr

Expert Opinion on Investigational Drugs
|September 28, 2005
PubMed
Summary

Vinflunine, a novel bi-fluorinated agent targeting tubulin, shows promising activity in solid tumors. Clinical trials are ongoing for bladder, lung, and breast cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations.

The New England journal of medicine·2026
Same author

ILD with datopotamab deruxtecan combinations: a warning signal we should not ignore.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Correction: Vaccine refusal in cancer patients at the French hospital: a normative re-analysis through a 'neopotterian theory of global bioethics'.

Monash bioethics review·2025
Same author

Vaccine refusal in cancer patients at the French hospital: a normative re-analysis through a 'neopotterian theory of global bioethics'.

Monash bioethics review·2025
Same author

Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.

European journal of cancer (Oxford, England : 1990)·2025
Same author

A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.

Cell reports. Medicine·2025

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Vinflunine is a novel semi-synthetic vinca alkaloid derivative.
  • It is the first bi-fluorinated, tubulin-targeted agent developed.
  • Its synthesis involved super-acidic chemistry for selective difluorination.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of vinflunine in patients with solid tumors.
  • To investigate vinflunine's activity in various cancer types based on preclinical data.
  • To support the initiation of Phase III trials for vinflunine.

Main Methods:

  • Vinflunine was administered to patients with advanced solid tumors.
  • Phase II clinical studies were conducted to assess treatment response.

Related Experiment Videos

  • Ongoing Phase III trials are evaluating efficacy and safety in specific cancer types.

    • Main Results:

    • Clinically significant activity was observed in Phase II studies.
    • Positive results were noted in patients with bladder, non-small cell lung, and breast cancers.
    • Preclinical data supported its selection for clinical development.

    Conclusions:

    • Vinflunine demonstrates clinically significant activity in several solid tumors.
    • The promising results have led to the initiation of Phase III clinical trials.
    • Vinflunine represents a promising new therapeutic option in oncology.